IBD 50: Valeant Taking The Buyout Route To Growth
at Investor's Business Daily - Fri Apr 25, 5:42PM CDT
Valeant Pharmaceuticals (VRX) is using buyouts to boost its business. The diversified Canadian drugmaker has made a boatload of buyouts, including a couple of big ones. In August, Valeant wrapped up its $8.7 billion acquisition of eye-care giant...
Wachtell Sees 'Threat' in Ackman's Allergan Bid
at The Street - Fri Apr 25, 3:48PM CDT
Activist investor critic Wachtell Lipton said hedge fund Pershing Square Capital Management's role in Valeant Pharmaceuticals $45 billion bid for Allergan was a new threat to Corporate America.
AbbVie Beats on Q1 Earnings, Humira Soars - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 3:45PM CDT
AbbVie (ABBV) surpassed expectations in the first quarter on the back of strong Humira sales.
Novartis Misses on Earnings & Revs in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 11:00AM CDT
Novartis (NVS) reported first quarter 2014 earnings per share of $1.21. Core earnings per share came in at $1.31, up 6% from the year-ago period but missed the Zacks Consensus Estimate of $1.33.
Prestige Brands Acquires Insight for $750M
at The Street - Fri Apr 25, 10:52AM CDT
Deal for feminine care product maker caps an active week for pharmaceutical mergers.
AstraZeneca Misses Earnings But Up on Takeover Rumors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 9:30AM CDT
AstraZeneca's first-quarter 2014 core earnings of $1.17 per American Depositary Share missed the Zacks Consensus Estimate of $1.20.
Stockholder Rights Plan, Quarterly Results, Clinical Trial Results, Purchase Agreements, and New Contracts - Analyst Notes on Allergan, Gilead, Pfizer, Actavis and Express Scripts
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT) and Express Scripts Holding Company (NASDAQ: ESRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1586-100free.
Update on Glaxo/Theravance's COPD Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 5:33PM CDT
Glaxo (GSK) and partner Theravance (THRX) announced the initiation of a phase III study on Relvar Ellipta.
Inside Valeant Pharmaceuticals' Bid for Allergan
Brendan Mathews, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Earlier this week, Valeant Pharmaceutical made a public offer to buy rival Allergan . Let's review the major questions this huge potential deal raises, to see whether it's a smart move – and whether or not it'll actually happen. What is...
Valeant Eyes Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:40PM CDT
Shares of Allergan (AGN) gained 15.2% after Valeant Pharmaceuticals International, Inc. (VRX) and Pershing Square Capital Management, L.P made a formal proposal to acquire the former.
Valeant And Pershing Square Investor Meeting Webcast Replay And Presentations Now Available
CNW Group - Thu Apr 24, 2:16PM CDT
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) and Pershing Square Capital Management L.P. ("Pershing Square"
Eli Lilly Q1 Earnings In-Line, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 12:50PM CDT
Eli Lilly's (LLY) first quarter revenues were hurt by the genericization of two major products - Cymbalta and Evista.
Zimmer Bolts on Biomet for $13.4B
at The Street - Thu Apr 24, 10:47AM CDT
Sponsors Blackstone, TPG, KKR and Goldman forgo planned IPO in sale of orthopedic device maker.
Botox at the Center of Recent Healthcare M&A Flurry
at The Street - Thu Apr 24, 10:07AM CDT
How wrinkle reduction is at the crux of the recent M&A frenzy....
Jim Cramer's 'Mad Money' Recap: The Market's New Reality
at The Street - Wed Apr 23, 7:20PM CDT
Investors are focusing on the positive instead of the negative, Cramer says.
Encouraging Results from Pfizer's Xeljanz - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 5:20PM CDT
Pfizer Inc. (PFE) announced encouraging top-line results from two pivotal phase III studies from the OPT Program on Xeljanz.
Fitch Places Allergan's Ratings on Negative Watch
Business Wire - Wed Apr 23, 2:32PM CDT
Fitch Ratings has placed the ratings for Allergan Inc. (Allergan), including the 'A+' Issuer Default Rating (IDR), on Rating Watch Negative. The rating action stems from Valeant Pharmaceuticals International Inc.'s (Valeant) unsolicited offer to acquire Allergan for approximately $45.6 billion. The rating action applies to $2.1 billion of outstanding Allergan debt. A complete list of ratings is provided at the end of this release.
Can Allergan Find an Alternative To Valeant?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Apr 23, 1:30PM CDT
No one will accuse Valeant CEO Mike Pearson of lacking boldness. He has laid out a strategy for turning Valeant into one of the largest pharmaceutical/med-tech companies in the world and has proven more than willing to turn to bold...
Stock Market News for April 23, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 9:06AM CDT
Benchmarks ended higher on Tuesday boosted by better-than-expected corporate results